Format

Send to

Choose Destination
BMC Neurol. 2016 May 12;16:64. doi: 10.1186/s12883-016-0587-2.

Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial.

Author information

1
Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 100053, China.
2
Department of Neurology, Tangshan Gongren Hospital, Tangshan, 063000, China.
3
Department of Neurology, Civil Aviation General Hospital, Beijing, 100123, China.
4
Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 100053, China. hanying@xwh.ccmu.edu.cn.
5
Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, 100053, China. hanying@xwh.ccmu.edu.cn.

Abstract

BACKGROUND:

The ε4 allele of the Apolipoprotein E gene (APOE-ε4) is a potent genetic risk factor for sporadic Alzheimer's disease (AD). Amnestic mild cognitive impairment (aMCI) is an intermediate state between normal cognitive aging and dementia, which is easy to convert to AD dementia. It is an urgent problem in the field of cognitive neuroscience to reveal the conversion of aMCI-ε4 to AD. Based on our preliminary work, we will study the neuroimaging features in the special group of aMCI-ε4 with multi-modality magnetic resonance imaging (structural MRI, resting state-fMRI and diffusion tensor imaging) longitudinally.

METHODS/DESIGN:

In this study, 200 right-handed subjects who are diagnosed as aMCI with APOE-ε4 will be recruited at the memory clinic of the Neurology Department, XuanWu Hospital, Capital Medical University, Beijing, China. All subjects will undergo the neuroimaging and neuropsychological evaluation at a 1 year-interval for 3 years. The primary outcome measures are 1) Microstructural alterations revealed with multimodal MRI scans including structure MRI (sMRI), resting state functional MRI (rs-fMRI), diffusion tensor imaging (DTI); 2) neuropsychological evaluation, including the World Health Organization-University of California-LosAngeles Auditory Verbal Learning Test (WHO-UCLA AVLT), Addenbrook's cognitive examination-revised (ACE-R), mini-mental state examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating scale (CDR).

DISCUSSION:

This study is to find out the neuroimaging biomarker and the changing laws of the marker during the progress of aMCI-ε4 to AD, and the final purpose is to provide scientific evidence for new prevention, diagnosis and treatment of AD.

TRIAL REGISTRATION:

This study has been registered to ClinicalTrials.gov (NCT02225964, https://www.clinicaltrials.gov/ ) in August 24, 2014.

KEYWORDS:

APOE4 allele; Alzheimer’s disease; Amnestic mild cognitive impairment; Longitudinal study; Multimodality; Neuroimaging techniques

PMID:
27176479
PMCID:
PMC4866435
DOI:
10.1186/s12883-016-0587-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center